Équipe de rédaction
Lecture de 4 m
17 janvier 2025
Visionnement de 3 m
17 janvier 2025
8m Read
3 février 2025
Article
As a result of the COVID-19 pandemic, molecular point-of-care testing (POCT) has become increasingly prevalent in recent years. To meet the high demand for testing during the peak of the pandemic, healthcare facilities frequently utilized multiple testing platforms. However, as demand decreases, facilities are now focusing on streamlining and optimizing their testing strategies.
Molecular tests that utilize nucleic acid amplification, such as PCR tests, have been regarded as the “gold standard” due to their higher accuracy compared to other POCT methods. To ensure the best performance and deliver optimal clinical care, it is vital for facilities to control factors that could potentially affect test results when conducting molecular testing.
This guide will focus on molecular POCT approved for waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) criteria. CLIA-waived tests are simple to perform and have minimal risk of producing an incorrect result but are not error-proof. In this guide, we’ve laid out seven best practices to help you simplify the process of obtaining accurate and reliable molecular POCT results.